

Jicheng Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10026072/publications.pdf>

Version: 2024-02-01

27
papers

289
citations

933447

10
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

368
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring. <i>Clinical Infectious Diseases</i> , 2018, 67, S249-S255.	5.8	35
2	Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6619-6625.	3.2	32
3	Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. <i>Journal of Infection</i> , 2021, 82, 207-215.	3.3	24
4	Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2018, 40, 322-332.e5.	2.5	23
5	Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients. <i>Clinical Infectious Diseases</i> , 2018, 67, S256-S262.	5.8	18
6	Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1164-1174.e4.	2.5	18
7	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0035021.	3.2	18
8	Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery. <i>World Neurosurgery</i> , 2017, 98, 525-531.	1.3	16
9	An ultra-performance liquid chromatography-tandem mass spectrometry method to quantify vancomycin in human serum by minimizing the degradation product and matrix interference. <i>Bioanalysis</i> , 2019, 11, 941-955.	1.5	11
10	Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis. <i>Future Microbiology</i> , 2017, 12, 39-50.	2.0	10
11	Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0040921.	3.2	9
12	Quantification of levornidazole and its metabolites in human plasma and urine by ultra-performance liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 963, 119-127.	2.3	8
13	Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 607-616.	1.8	8
14	Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 224-228.	2.5	7
15	Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1081-1082, 87-100.	2.3	7
16	Determination of DPâ€VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLC-MS/MS: A clinical pharmacokinetics and excretion study. <i>Drug Testing and Analysis</i> , 2019, 11, 1035-1047.	2.6	7
17	A Randomized, Double-blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 317-325.	1.6	7
18	Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2021, 41, 89-97.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0243021.	3.2	5
20	Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal Anaerobic Infection. <i>Clinical Therapeutics</i> , 2018, 40, 1548-1555.	2.5	4
21	Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. <i>Clinical Therapeutics</i> , 2019, 41, 505-517.e0.	2.5	4
22	Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1079-1086.	1.9	4
23	Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2022, 13, 869237.	3.5	4
24	Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1336-1346.	2.5	3
25	Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 911-923.	4.0	1
26	FRI0422â€¦HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY. , 2019, , .		0
27	Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	1.4	0